Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Common Stock | Options Exercise | $336K | +11.1K | +14.54% | $30.17 | 87.6K | Feb 22, 2025 | Direct | F1 |
transaction | PFE | Common Stock | Tax liability | -$13.1K | -497 | -0.57% | $26.30 | 87.1K | Feb 22, 2025 | Direct | F2, F3 |
transaction | PFE | Common Stock | Tax liability | -$259K | -9.93K | -11.39% | $26.08 | 77.2K | Feb 22, 2025 | Direct | F4, F5 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -11.1K | -100% | $0.00 | 0 | Feb 22, 2025 | Common Stock | 11.1K | $30.17 | Direct |
Id | Content |
---|---|
F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
F3 | Price is the closing price of Pfizer common stock on February 21, 2025. |
F4 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
F5 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |